alopecia areata
Conditions
Interventions
Fire needle + Xiaoban tincture group (left quadrant of group 1):One hour before each acupuncture treatment, compound lidocaine cream will be applied to the selected alopecia area and treated with fire
Xiaoban tincture group (right quadrant of group 1):The operator will apply Xiaoban tincture to the local head affected area, 1mL each time (about 7 sprays), and start to smear from the center of the a
Fire needle group (left quadrant of group 2):One hour before each acupuncture treatment, compound lidocaine cream will be applied to the selected alopecia area and treated with fire needle.
Negative control group (right quadrant of group 2):The right quadrant of group 2 served as negative control without treatment.
Sponsors
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Patients who were primary cases in skin clinic without any treatment; (2) Age >= 18 years old, regardless of sex; (3) Patients who met the diagnostic criteria of localized alopecia areata: the number of alopecia plaques >= 2, plaque diameter >= 1.5cm, alopecia area < 50%; (4) Patients who voluntarily participated in this study, signed a written informed consent form, and were willing to cooperate with the follow-up.
Exclusion criteria
Exclusion criteria: (1) Patients with Alopecia Areata (AA) except localized type; (2) Patients with other forms of patchy alopecia (such as trichomadesis, traction alopecia, syphilitic alopecia); (3) Patients with obvious spontaneous regeneration of peripheral hair; (4) Patients who received intrafocal or systemic corticosteroids or any alopecia areata treatment 2 months before the study; (5) Patients with another skin disease affecting the scalp, such as eczema; (6) Patients with diabetes or severe liver and kidney disease; (7) Patients with hemorrhage; (8) Patients who have a history of immunodeficiency diseases (such as HIV, etc.), or a history of cancer, malignant tumors, or autoimmune diseases, or severe cardiovascular or cerebrovascular diseases, or other diseases that may significantly reduce life expectancy; (IX) Patients who have any history of diseases that may affect programme compliance (such as severe mental disorders, cognitive impairment, substance abuse or addiction, etc.); (10) Pregnant or lactating women, or fertile women who are unwilling / unable to use effective contraceptive measures; (11) Patients who known to be allergic to Xiaoban tincture, lidocaine cream, iodophor or 75% alcohol in this study; (12)Patients who have participated in any drug clinical trial in the 6 months prior to the screening test; (13) Patients with dizzy needles.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effective rate of clinical efficacy; | — |
Secondary
| Measure | Time frame |
|---|---|
| The number of malnourished hair in alopecia area under dermatoscope;Dermatology Life Quality Index(DLQI);Visual Analogue Scale;Initial reaction time of hair regeneration;Patient satisfaction;Percentage of hair regeneration; | — |
Countries
China
Contacts
Public ContactLiu Jing
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Outcome results
None listed